Drugs / UD TGFbetai NK cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05588453 | Mar 2023 → Apr 2027 expected | cutaneous melanoma, metastatic malignant neoplasm in the brain, metastatic melanoma | Kari Kendra | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UD TGFbetai NK cells | “Patients receive UD TGFbetai NK cells intravenously (IV) over 30 minutes on day 1 and temozolomide orally (PO) daily on days 1-5.” NCT05588453 ↗ |
| Modality | Cell therapy | “universal donor UD TGFbetai natural killer (NK) cells” NCT05588453 ↗ |
| Route | Intravenous | “UD TGFbetai NK cells intravenously (IV) over 30 minutes on day 1” NCT05588453 ↗ |